BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 54,892 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 54,892 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the transaction, the chief executive officer directly owned 240,743 shares of the company’s stock, valued at approximately $86,222,105.45. The trade was a 18.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Tuesday, August 11th, John Oyler sold 70,907 shares of BeOne Medicines stock. The shares were sold at an average price of $361.90, for a total value of $25,661,243.30.
• On Monday, August 10th, John Oyler sold 115,011 shares of BeOne Medicines stock. The shares were sold at an average price of $357.87, for a total value of $41,158,986.57.
• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The shares were sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.

BeOne Medicines Trading Down 0.1%

Shares of ONC stock opened at $359.05 on Thursday. The company has a market capitalization of $39.39 billion, a P/E ratio of 63.21 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $253.95 and a 12-month high of $385.22. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average price of $301.40 and a 200 day moving average price of $309.13.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. Research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Citigroup reissued an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Royal Bank Of Canada reduced their price objective on BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Barclays increased their target price on BeOne Medicines from $403.00 to $407.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BeOne Medicines has a consensus rating of “Buy” and an average target price of $402.14.

Institutional Trading of BeOne Medicines

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE bought a new position in BeOne Medicines in the 2nd quarter worth approximately $67,657,000. Man Group plc bought a new position in BeOne Medicines in the 2nd quarter valued at $59,031,000. BNP Paribas Financial Markets bought a new position in BeOne Medicines in the 2nd quarter valued at $38,337,000. First Trust Advisors LP increased its stake in shares of BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after buying an additional 115,601 shares during the period. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $26,034,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Key Stories Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne Medicines and Revolution Medicines announced a partnership covering the clinical development and regional commercialization of oncology therapies. The agreement could expand BeOne’s cancer-treatment portfolio and future commercial opportunities. BeOne and Revolution Medicines partner for oncology therapies
• Positive Sentiment: Revolution Medicines shares rose after the market evaluated the BeOne-funded Phase 3 RAS(ON) collaboration, suggesting investors view the partnership as strategically meaningful for advancing targeted oncology treatments. The indirect benefit to ONC is tied to potential pipeline growth and future commercialization. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The data does not indicate meaningful short-selling pressure, although the reported figures appear unusual and may have limited informational value.
• Negative Sentiment: CEO John Oyler sold 240,810 BeOne Medicines shares across transactions dated August 10–12 for approximately $86.5 million in total. The sales reduced his direct ownership substantially, which can weigh on investor sentiment; however, all three transactions were executed under a pre-arranged Rule 10b5-1 trading plan, reducing the signal that the sales reflect a new negative view of the company. SEC insider transaction filing

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.